Matthew C Pickering

List of Publications by Year
in descending order

120	8,976	38742 50	42399 92
papers	citations	h-index	g-index

125	125	125	6876
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	C3 glomerulopathy: consensus report. Kidney International, 2013, 84, 1079-1089.	5.2	505
2	Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nature Genetics, 2002, 31, 424-428.	21.4	461
3	Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector Differentiation. Immunity, 2013, 39, 1143-1157.	14.3	444
4	C3 glomerulopathy: a new classification. Nature Reviews Nephrology, 2010, 6, 494-499.	9.6	314
5	Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet, The, 2010, 376, 794-801.	13.7	298
6	Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. Journal of Experimental Medicine, 2007, 204, 1249-1256.	8.5	267
7	Complement in human diseases: Lessons from complement deficiencies. Molecular Immunology, 2009, 46, 2774-2783.	2.2	250
8	Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4685-4690.	7.1	243
9	Atypical aHUS: State of the art. Molecular Immunology, 2015, 67, 31-42.	2.2	236
10	New Approaches to the Treatment of Dense Deposit Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 2447-2456.	6.1	231
11	C3 glomerulopathy â€" understanding a rare complement-driven renal disease. Nature Reviews Nephrology, 2019, 15, 129-143.	9.6	223
12	Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16651-16656.	7.1	201
13	C3 Glomerulopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 46-53.	4.5	192
14	C3 glomerulopathyâ€"associated CFHR1 mutation alters FHR oligomerization and complement regulation. Journal of Clinical Investigation, 2013, 123, 2434-2446.	8.2	176
15	Translational Mini-Review Series on Complement Factor H: Renal diseases associated with complement factor H: novel insights from humans and animals. Clinical and Experimental Immunology, 2008, 151, 210-230.	2.6	165
16	The complement system as a potential therapeutic target in rheumatic disease. Nature Reviews Rheumatology, 2017, 13, 538-547.	8.0	147
17	Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9649-9654.	7.1	144
18	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 281-295.	5.2	135

#	Article	IF	Citations
19	Complement Factor H Inhibits CD47-Mediated Resolution of Inflammation. Immunity, 2017, 46, 261-272.	14.3	132
20	High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. Journal of the American Society of Nephrology: JASN, 2020, 31, 1969-1975.	6.1	128
21	A Hybrid CFHR3-1 Gene Causes Familial C3 Glomerulopathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1155-1160.	6.1	120
22	Factor I is required for the development of membranoproliferative glomerulonephritis in factor Hâ€“deficient mice. Journal of Clinical Investigation, 2008, 118, 608-18.	8.2	118
23	P2X7 Deficiency Attenuates Renal Injury in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2009, 20, 1275-1281.	6.1	105
24	The Development of Atypical Hemolytic Uremic Syndrome Depends on Complement C5. Journal of the American Society of Nephrology: JASN, 2011, 22, 137-145.	6.1	105
25	Circulating complement factor Hâ€“related proteins 1Âand 5 correlate with disease activity in IgA nephropathy. Kidney International, 2017, 92, 942-952.	5.2	99
26	Acute Presentation and Persistent Glomerulonephritis Following Streptococcal Infection in a Patient With Heterozygous Complement Factor Hâ€“Related Protein 5 Deficiency. American Journal of Kidney Diseases, 2012, 60, 121-125.	1.9	95
27	Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney International, 2010, 78, 279-286.	5.2	94
28	Histopathology of MPGN and C3 glomerulopathies. Nature Reviews Nephrology, 2015, 11, 14-22.	9.6	91
29	Complement Component C3 Plays a Critical Role in Protecting the Aging Retina in a Murine Model of Age-Related Macular Degeneration. American Journal of Pathology, 2013, 183, 480-492.	3.8	81
30	Dense deposit disease. Molecular Immunology, 2011, 48, 1604-1610.	2.2	80
31	The role of complement in C3 glomerulopathy. Molecular Immunology, 2015, 67, 21-30.	2.2	78
32	Detection of complement activation using monoclonal antibodies against C3d. Journal of Clinical Investigation, 2013, 123, 2218-2230.	8.2	78
33	The role of complement in IgA nephropathy. Molecular Immunology, 2019, 114, 123-132.	2.2	76
34	Factor Hâ€“Related Protein 5 Interacts with Pentraxin 3 and the Extracellular Matrix and Modulates Complement Activation. Journal of Immunology, 2015, 194, 4963-4973.	0.8	75
35	Complement and glomerular disease: new insights. Current Opinion in Nephrology and Hypertension, 2011, 20, 271-277.	2.0	71
36	Recent insights into C3 glomerulopathy. Nephrology Dialysis Transplantation, 2013, 28, 1685-1693.	0.7	70

#	Article	IF	Citations
37	The follicular dendritic cell restricted epitope, FDC-M2, is complement C4; localization of immune complexes in mouse tissues. European Journal of Immunology, 2002, 32, 1883.	2.9	68
38	A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney International, 2014, 85, 933-937.	5.2	61
39	Phagocytosis Is the Main CR3-Mediated Function Affected by the Lupus-Associated Variant of CD11b in Human Myeloid Cells. PLoS ONE, 2013, 8, e57082.	2.5	58
40	An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. Kidney International, 2015, 88, 1314-1322.	5.2	58
41	Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death. ELife, 2021, 10, .	6.0	58
42	Complement Factor H Limits Immune Complex Deposition and Prevents Inflammation and Scarring in Glomeruli of Mice with Chronic Serum Sickness. Journal of the American Society of Nephrology: JASN, 2005, 16, 52-57.	6.1	57
43	Dense Deposit Disease and C3 Glomerulopathy. Seminars in Nephrology, 2013, 33, 493-507.	1.6	57
44	Progressive IgA Nephropathy Is Associated With Low Circulating Mannan-Binding Lectinâ€“Associated Serine Protease-3 (MASP-3) and Increased Glomerular Factor Hâ€“Related Protein-5 (FHR5) Deposition. Kidney International Reports, 2018, 3, 426-438.	0.8	57
45	Circulating complement factor Hâ€“related protein 5 levels contribute to development and progression of IgA nephropathy. Kidney International, 2018, 94, 150-158.	5.2	57
46	Continual Low-Level Activation of the Classical Complement Pathway. Journal of Experimental Medicine, 2001, 194, 747-756.	8.5	56
47	Type I interferons affect the metabolic fitness of CD8+ T cells from patients with systemic lupus erythematosus. Nature Communications, 2021, 12, 1980.	12.8	56
48	The complement factor Hâ€•related proteins. Immunological Reviews, 2016, 274, 191-201.	6.0	54
49	SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience. Rheumatology, 2010, 49, 823-824.	1.9	53
50	Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney International, 2011, 80, 165-173.	5.2	53
51	Design and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen Molecules. PLoS Pathogens, 2012, 8, e1002981.	4.7	53
52	Are anti-C1q antibodies different from other SLE autoantibodies?. Nature Reviews Rheumatology, 2010, 6, 490-493.	8.0	52
53	Update on C3 glomerulopathy. Nephrology Dialysis Transplantation, 2016, 31, 717-725.	0.7	52
54	C3 Glomerulopathy: The Genetic and Clinical Findings in Dense Deposit Disease and C3 Glomerulonephritis. Seminars in Thrombosis and Hemostasis, 2014, 40, 465-471.	2.7	50

#	Article	IF	Citations
55	Competition between antagonistic complement factors for a single protein on N. meningitidis rules disease susceptibility. ELife, 2014, 3, .	6.0	50
56	Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. Kidney International, 2012, 81, 152-159.	5.2	47
57	Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase. Molecular Immunology, 2009, 46, 1942-1950.	2.2	46
58	Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene. Journal of Human Genetics, 2012, 57, 459-464.	2.3	43
59	Complement activation in IgA nephropathy. Seminars in Immunopathology, 2021, 43, 679-690.	6.1	42
60	Decay-Accelerating Factor Suppresses Complement C3 Activation and Retards Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. American Journal of Pathology, 2009, 175, 1757-1767.	3.8	41
61	IgM exacerbates glomerular disease progression in complement-induced glomerulopathy. Kidney International, 2015, 88, 528-537.	5.2	41
62	An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. Journal of the American Society of Nephrology: JASN, 2018, 29, 1649-1661.	6.1	41
63	Ultraviolet-Radiation-Induced Keratinocyte Apoptosis in C1q-Deficient Mice. Journal of Investigative Dermatology, 2001, 117, 52-58.	0.7	40
64	Eculizumab as rescue therapy in severe resistant lupus nephritis: Fig. 1. Rheumatology, 2015, 54, kev307.	1.9	40
65	Triglyceride-Rich Lipoproteins Modulate the Distribution and Extravasation of Ly6C/Gr1low Monocytes. Cell Reports, 2015, 12, 1802-1815.	6.4	33
66	Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis. Kidney International, 2019, 95, 655-665.	5.2	33
67	O- and N-Glycosylation of Serum Immunoglobulin A is Associated with IgA Nephropathy and Glomerular Function. Journal of the American Society of Nephrology: JASN, 2021, 32, 2455-2465.	6.1	33
68	Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy. Journal of the American Society of Nephrology: JASN, 2016, 27, 1334-1342.	6.1	30
69	Complement factor Hâ€“deficient mice develop spontaneous hepatic tumors. Journal of Clinical Investigation, 2020, 130, 4039-4054.	8.2	30
70	Regulating complement in the kidney: insights from CFHR5 nephropathy. DMM Disease Models and Mechanisms, 2011, 4, 721-726.	2.4	27
71	C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independentin vivo. Clinical and Experimental Immunology, 2014, 176, 84-92.	2.6	27
72	IgA1 Glycosylation Is Heritable in Healthy Twins. Journal of the American Society of Nephrology: JASN, 2017, 28, 64-68.	6.1	27

#	Article	IF	Citations
73	Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy. Journal of the American Society of Nephrology: JASN, 2016, 27, 405-416.	6.1	26
74	Essential Role of Surface-Bound Complement Factor H in Controlling Immune Complexâ€“Induced Arthritis. Journal of Immunology, 2013, 190, 3560-3569.	0.8	23
75	Nonfunctional Variant 3 Factor H Binding Proteins as Meningococcal Vaccine Candidates. Infection and Immunity, 2014, 82, 1157-1163.	2.2	23
76	Autoantibody-dependent amplification of inflammation in SLE. Cell Death and Disease, 2020, 11, 729.	6.3	23
77	Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. Journal of Clinical Investigation, 2019, 129, 1061-1075.	8.2	23
78	Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Molecular Immunology, 2009, 46, 803-811.	2.2	22
79	Complement Factor H Serum Levels Determine Resistance to Pneumococcal Invasive Disease. Journal of Infectious Diseases, 2016, 213, 1820-1827.	4.0	17
80	Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM. European Journal of Immunology, 2018, 48, 791-802.	2.9	17
81	Glomerular Complement Factor Hâ€“Related Protein 5 (FHR5) Is Highly Prevalent in C3 Glomerulopathy and Associated With Renal Impairment. Kidney International Reports, 2019, 4, 1387-1400.	0.8	17
82	Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. Kidney International, 2016, 90, 109-122.	5.2	16
83	Annexin A2 Enhances Complement Activation by Inhibiting Factor H. Journal of Immunology, 2016, 196, 1355-1365.	0.8	16
84	Gain-of-function factor Hâ€“related 5 protein impairs glomerular complement regulation resulting in kidney damage. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	15
85	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	1.9	15
86	Complement factor H contributes to mortality in humans and mice with bacterial meningitis. Journal of Neuroinflammation, 2019, 16, 279.	7.2	13
87	Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 994-1007.	4.5	13
88	Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patientsâ€”a potential biomarker of disease activity. Rheumatology, 2017, 56, 1206-1216.	1.9	12
89	Complement Factor H Modulates Splenic B Cell Development and Limits Autoantibody Production. Frontiers in Immunology, 2019, 10, 1607.	4.8	12
90	C3 Glomerulopathy and Related Disorders in Children. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1639-1651.	4.5	12

#	Article	IF	Citations
91	Factor Hâ€“Related Protein 1 Drives Disease Susceptibility and Prognosis in C3 Glomerulopathy. Journal of the American Society of Nephrology: JASN, 2022, 33, 1137-1153.	6.1	12
92	Experimental Models of Membranoproliferative Glomerulonephritis, Including Dense Deposit Disease. Contributions To Nephrology, 2011, 169, 198-210.	1.1	11
93	Clusters Not Classifications: Making Sense of Complement-Mediated Kidney Injury. Journal of the American Society of Nephrology: JASN, 2018, 29, 9-12.	6.1	10
94	Complement Regulatory Protein Factor H Is a Soluble Prion Receptor That Potentiates Peripheral Prion Pathogenesis. Journal of Immunology, 2017, 199, 3821-3827.	0.8	9
95	Defining the Glycosaminoglycan Interactions of Complement Factor Hâ€“Related Protein 5. Journal of Immunology, 2021, 207, 534-541.	0.8	9
96	Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis. Frontiers in Immunology, 2020, 11, 1772.	4.8	8
97	Murine Factor H Co-Produced in Yeast With Protein Disulfide Isomerase Ameliorated C3 Dysregulation in Factor H-Deficient Mice. Frontiers in Immunology, 2021, 12, 681098.	4.8	8
98	Atypical hemolytic uremic syndrome: telling the difference between H and Y. Kidney International, 2010, 78, 721-723.	5.2	7
99	Complement receptor 3 mediates renal protection in experimental C3 glomerulopathy. Kidney International, 2016, 89, 823-832.	5.2	7
100	Adeno-Associated Virus Vector Gene Delivery Elevates Factor I Levels and Downregulates the Complement Alternative PathwayIn Vivo. Human Gene Therapy, 2021, 32, 1370-1381.	2.7	7
101	Homodimeric Minimal Factor H: In Vivo Tracking and Extended Dosing Studies in Factor H Deficient Mice. Frontiers in Immunology, 2021, 12, 752916.	4.8	7
102	Relationship between complotype and reported severity of systemic allergic reactions to peanut. Journal of Allergy and Clinical Immunology, 2012, 129, 1398-1401.e3.	2.9	5
103	SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19. Kidney Medicine, 2021, 3, 54-59.e1.	2.0	5
104	Complement and kidney disease, new insights. Current Opinion in Nephrology and Hypertension, 2021, 30, 310-316.	2.0	5
105	Complement activity is regulated in C3 glomerulopathy by IgGâ€“factor H fusion proteins with and without properdin targeting domains. Kidney International, 2021, 99, 396-404.	5.2	4
106	Lateral medullary syndrome with anti-neuronal antibodies (anti-Ta/Ma2) in primary Sjogren's syndrome. Rheumatology, 2009, 48, 1174-1176.	1.9	3
107	Complement alternative pathway genetic variation and D engue infection in the T hai population. Clinical and Experimental Immunology, 2013, 174, 326-334.	2.6	3
108	Immune gene expression and functional networks in distinct lupus nephritis classes. Lupus Science and Medicine, 2022, 9, e000615.	2.7	3

#	Article	IF	Citations
109	False-positive results obtained using the Mantoux test in BehÃ§et's syndrome: Comment on the article by GarcÃa-PorrÃºa et al. Arthritis and Rheumatism, 2000, 43, 2855-2855.	6.7	2
110	Painful myositis in the anti-synthetase syndrome with anti-PL12 antibodies. Rheumatology International, 2012, 32, 825-827.	3.0	2
111	Membranoproliferative and C3-Mediated GN in Children. , 2016, , 1035-1053.		2
112	Successful simultaneous liverâ€kidney transplantation for renal failure associated with hereditary complement C3 deficiency. American Journal of Transplantation, 2020, 20, 2260-2263.	4.7	2
113	MO126CLINICAL AND BIOMARKER CHARACTERISTICS OF PATIENTS WITH C3G OR IC-MPGN ENROLLED IN TWO PHASE II STUDIES INVESTIGATING THE FACTOR D INHIBITOR DANICOPAN*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	2
114	Complement activation during cardiopulmonary bypass and association with clinical outcomes. EJHaem, 2022, 3, 86-96.	1.0	2
115	Membranoproliferative Glomerulonephritis and C3 Glomerulopathy in Children. , 2021, , 1-31.		1
116	Conversion of the Liver into a Biofactory for DNaseI Using Adeno-Associated Virus Vector Gene Transfer Reduces Neutrophil Extracellular Traps in a Model of Systemic Lupus Erythematosus. Human Gene Therapy, 2022, 33, 560-571.	2.7	1
117	Genetic Manipulation. , 2006, , 563-589.		0
118	Disorders of complement regulation. Drug Discovery Today: Disease Models, 2014, 11, 29-35.	1.2	0
119	Membranoproliferative and C3-Mediated GN in Children. , 2015, , 1-22.		0
120	ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A Â«KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMESÂ» (KDIGO) CONTROVERSIES CONFERENCE. Nephrology (Saint-Petersburg), 2018, 22, 18-39.	0.4	0